Bio-Techne (TECH) AI Stock Analysis

• Market Cap: $8.16B
• Dividend Yield: 0.6%
• Average Volume (3M): 1.90M
• Price to Earnings (P/E): 63.4
• Beta (1Y): 0.91
• Revenue Growth: 4.72%
• EPS Growth: -35.33%
• Country: US
• Employees: 3,100
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.56
• Shares Outstanding: 156,767,290
• 10 Day Avg. Volume: 1,595,922
• 30 Day Avg. Volume: 1,904,345
• PEG Ratio: -3.62
• Price to Book (P/B): 4.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 36.52
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 1.76
• Enterprise Value/Gross Profit: 10.48
• Enterprise Value/Ebitda: 6.12
• 1Y Price Target: $67.70
• Price Target Upside: 27.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 75 Outperform
• Price Target: $60.00 ▲(12.95%Upside)

Bio-Techne's overall stock score is supported by strong financial performance and strategic resilience highlighted in the earnings call. While technical indicators and high valuation present some caution, the company's growth prospects and financial management remain robust.

Positive Factors

Growth Potential

TECH's unique portfolio is well-positioned to deliver sustained above-average organic revenue and EPS growth.

Valuation

The recent pullback in TECH's share price offers a compelling entry point as it trades below its historical average, indicating an attractive investment opportunity.

Negative Factors

Government Impact

TECH has exposure to US ACA/government end-market, which has weighed heavily on the stock.

Market Challenges

The sector continues to face headwinds such as NIH funding, Pharma tariffs, biotech funding, and China macro.

Bio-Techne Business Overview & Revenue Model

Company Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

How the Company Makes Money

Bio-Techne makes money primarily through the sale of its diverse range of biotechnology products and solutions. Key revenue streams include sales of proteins and antibodies, which are essential components for research and development in life sciences. The company also generates significant income from its immunoassay and diagnostic products, which are widely used in clinical settings to detect and quantify biological markers. Additionally, Bio-Techne benefits from partnerships and collaborations with academic institutions, research organizations, and pharmaceutical companies, enhancing its market reach and contributing to its earnings.

Bio-Techne Financial Statement Overview

Summary

Bio-Techne demonstrates strong profitability with robust margins and efficient asset management. Low leverage and solid profit margins position the company well, though challenges like a slight decline in net income and free cash flow growth need addressing.

Income Statement

Bio-Techne exhibits strong profitability with a consistent Gross Profit Margin above 65% and a healthy Net Profit Margin around 10-12% over the years. The Revenue Growth Rate is notable, with a TTM growth of approximately 4.3% compared to the previous annual report. EBIT and EBITDA margins are robust, reflecting operational efficiency. However, a slight decline in net income in the TTM indicates potential challenges in managing costs or market pressures.

Balance Sheet

The company maintains a solid financial structure with a stable Debt-to-Equity Ratio of approximately 0.21, indicating low leverage. The Equity Ratio has strengthened to about 76.3%, showcasing healthy asset management. Return on Equity (ROE) is slightly decreasing, from 16.8% in 2023 to 6.5% in TTM, which may be a concern regarding profitability and asset utilization efficiency.

Cash Flow

Bio-Techne's cash flow position is strong, with positive Free Cash Flow and an Operating Cash Flow to Net Income Ratio of approximately 2.01 in TTM, indicating effective cash management. However, the Free Cash Flow Growth Rate is slightly negative, suggesting room for improvement in cash generation activities.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	1.16B	1.14B	1.11B	931.03M	738.69M
Gross Profit	769.73M	769.82M	756.50M	632.85M	483.19M
EBITDA	310.37M	460.56M	420.12M	258.47M	373.91M
Net Income	168.10M	285.26M	272.05M	140.41M	229.30M
Balance Sheet
Total Assets	2.70B	2.64B	2.29B	2.26B	2.03B
Cash, Cash Equivalents and Short-Term Investments	152.86M	204.31M	247.03M	231.55M	270.89M
Total Debt	419.54M	454.96M	325.97M	420.55M	433.53M
Total Liabilities	635.02M	672.18M	593.79M	691.72M	646.40M
Stockholders Equity	2.07B	1.97B	1.70B	1.57B	1.38B
Cash Flow
Free Cash Flow	236.10M	216.15M	280.36M	307.86M	153.47M
Operating Cash Flow	298.98M	254.39M	325.27M	352.16M	205.22M
Investing Cash Flow	-203.03M	-265.65M	-96.85M	-243.52M	27.09M
Financing Cash Flow	-122.40M	22.62M	-242.85M	-62.55M	-183.80M

Bio-Techne Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 53.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECH, the sentiment is Positive. The current price of 53.12 is above the 20-day moving average (MA) of 52.31, above the 50-day MA of 50.58, and below the 200-day MA of 62.82, indicating a neutral trend. The MACD of 0.41 indicates Positive momentum. The RSI at 54.37 is Neutral, neither overbought nor oversold. The STOCH value of 31.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TECH.

Bio-Techne Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	80 Outperform	$4.39B	36.58	13.90%	―	247.53%	118.34%
BMRN	77 Outperform	$10.99B	20.99	9.64%	―	17.99%	152.10%
TECH	75 Outperform	$8.16B	63.41	6.53%	0.60%	4.72%	-35.33%
INCY	73 Outperform	$13.14B	208.48	0.47%	―	17.13%	-88.78%
NAMS	65 Neutral	$2.49B	―	-31.51%	―	―	―
MRNA	55 Neutral	$12.09B	―	-29.34%	―	-38.25%	44.29%
Sector *	52 Neutral	$7.46B	-0.04	-63.82%	2.49%	16.43%	<0.01%

Bio-Techne Corporate Events

Bio-Techne Reports Q3 2025 Financial Results

On May 7, 2025, Bio-Techne Corporation announced its financial results for the third quarter of fiscal 2025, reporting a 6% increase in organic revenue to $316.2 million. The company saw a decline in GAAP earnings per share to $0.14 from $0.31 a year ago, but adjusted EPS rose to $0.56. The Protein Sciences segment experienced 7% organic growth, driven by improved pharma market conditions and strong commercial execution. The adjusted operating margin increased to 34.9%, reflecting profitability initiatives and volume leverage. Despite a challenging macroenvironment, Bio-Techne’s strategic positioning and leadership are expected to help navigate current conditions, enhancing its financial performance and market presence.

Bio-Techne Announces New $500M Share Repurchase Program

On April 30, 2025, Bio-Techne Corporation’s Board of Directors authorized a new share repurchase program, allowing the company to buy back up to $500 million of its common stock. This program replaces the previous one from February 2022 and has no set time limit. The repurchases can be made through various methods, including open market and private transactions, and are subject to market conditions and the company’s financial performance. The initiative aims to manage stock dilution and optimize capital needs, with disclosures to be made in the company’s annual and quarterly reports.